News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
271,104 Results
Type
Article (14331)
Company Profile (106)
Press Release (256662)
Multimedia
Podcasts (60)
Webinars (13)
Section
Business (88608)
Career Advice (492)
Deals (15433)
Drug Delivery (68)
Drug Development (36922)
Employer Resources (54)
FDA (6371)
Job Trends (6289)
News (151250)
Policy (14139)
Tag
Academia (446)
Accelerated approval (8)
Adcomms (7)
Allergies (50)
Alliances (23411)
ALS (49)
Alzheimer's disease (450)
Antibody-drug conjugate (ADC) (67)
Approvals (6450)
Artificial intelligence (149)
Autoimmune disease (15)
Automation (6)
Bankruptcy (150)
Best Places to Work (4407)
BIOSECURE Act (10)
Biosimilars (79)
Biotechnology (41)
Bladder cancer (27)
Brain cancer (23)
Breast cancer (117)
Cancer (957)
Cardiovascular disease (112)
Career advice (429)
Career pathing (14)
CAR-T (35)
CDC (4)
Cell therapy (115)
Cervical cancer (6)
Clinical research (31595)
Collaboration (511)
Compensation (241)
Complete response letters (23)
COVID-19 (781)
CRISPR (34)
C-suite (257)
Cystic fibrosis (49)
Data (1100)
Denatured (16)
Depression (25)
Diabetes (99)
Diagnostics (1349)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (16)
Drug discovery (79)
Drug pricing (91)
Drug shortages (12)
Duchenne muscular dystrophy (64)
Earnings (33092)
Editorial (16)
Employer branding (6)
Employer resources (49)
Events (38426)
Executive appointments (490)
FDA (7145)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (313)
Gene editing (55)
Generative AI (9)
Gene therapy (133)
GLP-1 (400)
Government (1372)
Grass and pollen (4)
Guidances (136)
Healthcare (3621)
HIV (7)
Huntington's disease (6)
IgA nephropathy (22)
Immunology and inflammation (58)
Immuno-oncology (2)
Indications (24)
Infectious disease (824)
Inflammatory bowel disease (63)
Inflation Reduction Act (7)
Influenza (17)
Intellectual property (74)
Interviews (62)
IPO (5940)
IRA (33)
Job creations (2071)
Job search strategy (387)
Kidney cancer (7)
Labor market (25)
Layoffs (206)
Leadership (6)
Legal (3452)
Liver cancer (21)
Longevity (6)
Lung cancer (137)
Lymphoma (86)
Machine learning (5)
Management (17)
Manufacturing (267)
MASH (49)
Medical device (1293)
Medtech (1295)
Mergers & acquisitions (9797)
Metabolic disorders (335)
Multiple sclerosis (33)
NASH (14)
Neurodegenerative disease (47)
Neuropsychiatric disorders (16)
Neuroscience (736)
NextGen: Class of 2025 (1600)
Non-profit (609)
Now hiring (37)
Obesity (186)
Opinion (136)
Ovarian cancer (28)
Pain (85)
Pancreatic cancer (30)
Parkinson's disease (55)
Partnered (8)
Patents (170)
Patient recruitment (69)
Peanut (12)
People (29510)
Pharmaceutical (65)
Pharmacy benefit managers (14)
Phase I (8235)
Phase II (13349)
Phase III (12016)
Pipeline (952)
Policy (113)
Postmarket research (1404)
Preclinical (3320)
Press Release (25)
Prostate cancer (67)
Psychedelics (12)
Radiopharmaceuticals (127)
Rare diseases (239)
Real estate (2654)
Recruiting (19)
Regulatory (10500)
Reports (15)
Research institute (573)
Resumes & cover letters (60)
Rett syndrome (2)
RNA editing (5)
RSV (11)
Schizophrenia (52)
Series A (56)
Series B (29)
Service/supplier (3)
Sickle cell disease (38)
Special edition (9)
Spinal muscular atrophy (80)
Sponsored (7)
Startups (1644)
State (2)
Stomach cancer (3)
Supply chain (39)
Tariffs (60)
The Weekly (42)
Vaccines (209)
Venture capital (23)
Weight loss (113)
Women's health (11)
Worklife (4)
Date
Last 7 days (168)
Last 30 days (701)
Last 365 days (11049)
2025 (7741)
2024 (12658)
2023 (14420)
2022 (19708)
2021 (20224)
2020 (19124)
2019 (14969)
2018 (11766)
2017 (13959)
2016 (13165)
2015 (15529)
2014 (12446)
2013 (10609)
2012 (11440)
2011 (11948)
2010 (10909)
Location
Africa (318)
Alabama (18)
Alaska (1)
Arizona (66)
Arkansas (3)
Asia (20570)
Australia (2648)
California (2454)
Canada (1210)
China (397)
Colorado (98)
Connecticut (103)
Delaware (89)
Europe (40342)
Florida (473)
Georgia (56)
Hawaii (1)
Idaho (9)
Illinois (279)
India (24)
Indiana (180)
Iowa (1)
Japan (154)
Kansas (67)
Kentucky (17)
Louisiana (2)
Maine (2)
Maryland (346)
Massachusetts (2120)
Michigan (37)
Minnesota (134)
Mississippi (1)
Missouri (26)
Montana (8)
Nebraska (6)
Nevada (13)
New Hampshire (7)
New Jersey (1088)
New Mexico (8)
New York (700)
North Carolina (498)
North Dakota (2)
Northern California (1040)
Ohio (61)
Oklahoma (5)
Oregon (16)
Pennsylvania (586)
Puerto Rico (9)
Rhode Island (14)
South America (506)
South Carolina (6)
Southern California (1049)
Tennessee (43)
Texas (353)
United States (10067)
Utah (50)
Virginia (124)
Washington D.C. (40)
Washington State (163)
West Virginia (1)
Wisconsin (24)
271,104 Results for "takeda pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial
Presenting at the World Sleep Congress 2025, the Dublin-based company’s Phase II study bested Takeda drug in both efficacy and safety.
September 8, 2025
·
2 min read
·
Dan Samorodnitsky
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.
July 14, 2025
·
2 min read
·
Tristan Manalac
Earnings
Takeda Pledges $30B in U.S., Argues Against Trump’s ‘Most Favored Nation’ Proposal
Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 trillion over the next 10 years.
May 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
September 12, 2025
·
6 min read
Press Releases
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
September 5, 2025
·
4 min read
Press Releases
Takeda’s FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
August 29, 2025
·
5 min read
Press Releases
Takeda Announces New Assignments of Directors
June 25, 2025
·
6 min read
Collaboration
Takeda Pumps $770M Into Another BridGene Pact to Hit ‘Undruggable’ Targets
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in the past nine months.
February 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
July 30, 2025
·
10 min read
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
·
2 min read
·
Annalee Armstrong
1 of 27,111
Next
